Closing the Middle East and north Africa representation gap in clinical trials in inflammatory bowel disease [0.03%]
弥合中东和北非炎症性肠病临床试验中的代表性差距
Mohammad Shebab,Ahmed Al-Hindawi,Shane W Goodwin et al.
Mohammad Shebab et al.
Stephanie A Vuijk,Esmée H Boute,Lissy de Ridder
Stephanie A Vuijk
Efficacy and safety of mirikizumab in paediatric participants with moderately-to-severely active ulcerative colitis (SHINE-1): a multicentre, open-label, non-randomised phase 2 trial [0.03%]
mirikizumab治疗中至重度活动性溃疡性结肠炎儿科患者的有效性和安全性（SHINE-1）：一项多中心、开放标签、非随机Ⅱ期试验
Jess L Kaplan,Athos Bousvaros,Dan Turner et al.
Jess L Kaplan et al.
Background: Mirikizumab, a humanised immunoglobulin G4 monoclonal antibody, targets the p19 subunit of IL-23, with demonstrated efficacy and safety in adults with ulcerative colitis and Crohn's disease. This study evaluat...
Colorectal cancer screening in LGBTQIA+ people: an urgent call for equity [0.03%]
呼吁对LGBTQIA+人群进行结直肠癌筛查以实现平等权益
Vidhi Singh,Jayraan Badiee,Alexander Goldowsky et al.
Vidhi Singh et al.
The essential medicines list for inflammatory bowel disease: time to raise the standards of global care [0.03%]
炎性肠病基本药物目录：是时候提高全球治疗标准了
Nanne K de Boer,Richard B Gearry,Charles N Bernstein et al.
Nanne K de Boer et al.
Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial [0.03%]
口服TNF和IL-23双特异性抑制剂SOR102在健康志愿者及溃疡性结肠炎患者中的安全性与药动学：一项随机、双盲、安慰剂对照的首次人体Ⅰ期临床试验
Vipul Jairath,Silvio Danese,Geert R D&#x;Haens et al.
Vipul Jairath et al.
Background: SOR102 is an oral bispecific antibody comprised of single domain antibodies targeting TNF and interleukin (IL)-23p19. We aimed to assess the safety, pharmacokinetics, clinical, and biological activity of SOR10...
Dual targeting of TNF and IL-23 by a bispecific antibody in ulcerative colitis [0.03%]
一种双特异性抗体通过同时靶向TNF和IL-23治疗溃疡性结肠炎
Raja Atreya,Markus F Neurath
Raja Atreya
Endoscopist deskilling risk after exposure to artificial intelligence in colonoscopy - Authors' reply [0.03%]
内镜医生面临的风险：暴露于结肠镜检查人工智能后的技能退化——作者的回复
Krzysztof Budzyń,Marcin Romańczyk,Yuichi Mori
Krzysztof Budzyń
Endoscopist deskilling risk after exposure to artificial intelligence in colonoscopy [0.03%]
内镜医生在结肠镜检查中接触人工智能后的技能下降风险
Davy van de Sande,Stefan Sleijfer,Stefan N R Buijsman et al.
Davy van de Sande et al.
Endoscopist deskilling risk after exposure to artificial intelligence in colonoscopy [0.03%]
内镜医生在结肠镜检查中接触人工智能后的技能退化风险
Asaf Levartovsky,Uri Kopylov
Asaf Levartovsky